Enliven Therapeutics Director Lori Anne Kunkel Disposes of USD 504,256 Common Shares

Senestech CEO Michael Edell Acquires 1,000 Common Shares Worth $1,429.90

Tarsus Publishes Investor Presentation on Irenix Acquisition, Irx-101 Ocular Antiseptic Program

Janus Living Declares Monthly Dividends of $0.0475 a Share for Q3

Alumis Chief Legal Officer Sanam Pangali Disposes of Common Shares Worth $140,000

Eli Lilly: Q2 2026 Acquired Ipr&d Charges Estimated at $2.80b Pre-tax

Lilly Expects Q2 Acquired IPR&D Charge of About $2.8 Billion Pretax, $3.02/sh Hit

Alector Ends GSK Collaboration, Retires Hercules Capital Debt

Liquidia Director Stephen M. Bloch Reports Disposal of 75,000 Common Shares Worth $6.02 Million

Hepion Pharmaceuticals Director Danina Fisher Files Initial Beneficial Ownership Statement

Range Impact Names Vin Ferrara Vice President of Real Estate

Range Impact Announces Vin Ferrara, Md, MBA, Has Joined the Company as Vice President, Real Estate

Press Release: Janus Living Declares Monthly Common Stock Cash Dividends for the Third Quarter of 2026

Amneal, Adalvo Win FDA Review Acceptance for Generic Tirzepatide Autoinjector Andas

Theravance Biopharma 10% Owner Eli Samaha Disposes of USD 119,359 in Common Shares

Larimar Therapeutics director buys $167K in common stock

Tarsus Pharmaceuticals Buys Irenix Medical in Deal with USD 75 Million Upfront Payment

Rani Therapeutics Files Form 3 for CFO Nicholas Maestas on Initial Beneficial Ownership Statement

Tarsus Pharmaceuticals - Upfront Consideration for Deal Totals $75 Mln: $37.5 Mln Cash, $37.5 Mln Stock

Tarsus Pharmaceuticals - to Begin Phase 3 Irx-101 Study in H1 2027, Results Expected 2028